Clinical Trial: Comparison of Telavancin and Vancomycin for Hospital-Acquired Pneumonia Due to Methicillin-Resistant Staphylococcus Aureus (ATTAIN 2)

This study is currently recruiting patients.

Sponsored by: Theravance
Information provided by: Theravance


Study 0019 compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Condition Intervention Phase
Bacterial Pneumonia
 Drug: Telavancin
Phase III

MedlinePlus related topics:  Bacterial Infections;   Pneumonia

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus On Patients with Infections Due to Methicillin-Resistant Staphylococcus Aureus

Further Study Details: 
Primary Outcomes: Clinical response
Expected Total Enrollment:  625

Study start: January 2005


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Inclusion Criteria:

  • Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic-care facility

Exclusion Criteria:

Location and Contact Information

Please refer to this study by identifier  NCT00124020

Claudia Fuentes      650 808 6094

      Regional Infectious Diseases-Infusion Center, Lima,  Ohio,  45801,  United States; Recruiting
R. Scott Steinecker, MD

Study chairs or principal investigators

Ralph G. Corey, MD,  Principal Investigator,  Duke Clinical Research Center   

More Information

Study ID Numbers:  0019
Record last reviewed:  July 2005
Last Updated:  July 25, 2005
Record first received:  July 25, 2005 Identifier:  NCT00124020
Health Authority: United States: Food and Drug Administration processed this record on 2005-07-26


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us